emicizumab
Term · Oncology and biomedicine · MLC-T-ONC-013324
A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of hemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by coagulation factor VIII (FVIII); FVIII is missing in HA patients.
| Identifier | MLC-T-ONC-013324 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | emicizumab-kxwh |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013324",
"term": "emicizumab",
"field": "Oncology and biomedicine",
"definition": "A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of hemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by coagulation factor VIII (FVIII); FVIII is missing in HA patients.",
"synonyms": [
"emicizumab-kxwh"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/emicizumab/"
}
Record 6,593 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.